Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study

A novel GLP‐1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease

“…The study demonstrated that the disease‐induced decrease in glucose utilization in the brain was stopped by liraglutide (Gejl et al, ). Another pilot study in patients with mood disorders showed improvements in cognitive tasks and also in MRI brain scans, where cortical and subcortical brain areas were found to increase in volume (Mansur, Ahmed, et al, ; Mansur, Zugman et al, ). A phase II clinical trial in AD patients testing liraglutide is currently ongoing (Hölscher, ).…”

Effects of incretin-based therapies on neurocognitive function in humans: A systematic review of the literature

“…In an open-label study in 19 patients with comorbid affective disorder, 4 weeks of liraglutide was associated with improvements in multiple cognitive domains, although the study was uncontrolled [10]. In a cross-over trial of liraglutide versus placebo, 17 days of liraglutide was not associated with improvements on any measure of cognition compared to placebo [11].…”

BDNF and BMI effects on brain structures of bipolar offspring: results from the global mood and brain science initiative

“…The association between BDNF and neurostructural parameters was also moderated by offspring status and BMI. The moderational effect of BMI on the association between BDNF and brain structures reinforces the need to assess the impact of obesity/overweight in at‐risk populations and offers insights about possible interventions targeting weight and systemic metabolic disturbances that may reduce the risk for, or prevent the onset of, BD in at‐risk populations . Results from this study should inform the design of future studies on the early stages of BD and be confirmed or refuted by larger longitudinal studies.…”